drugset / Trial / NCT00004050
Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer
Phase 2
Terminated
13 enrolled
Vical
Jonsson Comprehensive Cancer Center · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Inserting the gene for interleukin-2 into a person's cancer cells may improve the body's ability to fight cancer. Using Leuvectin to deliver this gene may be an effective treatment for prostate cancer. PURPOSE: Phase II trial to study the effectiveness of Leuvectin followed by surgery in treating patients who have stage II or stage III prostate cancer.
Timeline
- Start
- 1999-06
- Primary completion
- 2003-04
- Completion
- 2003-04
Outcome
Outcome not reported
Stopped: “Development in prostate cancer indication halted”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuvectin | Other / unclassified | 1000 ug | Other |